Michel Préfontaine

974 total citations
42 papers, 734 citations indexed

About

Michel Préfontaine is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Surgery. According to data from OpenAlex, Michel Préfontaine has authored 42 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Obstetrics and Gynecology, 21 papers in Reproductive Medicine and 8 papers in Surgery. Recurrent topics in Michel Préfontaine's work include Ovarian cancer diagnosis and treatment (20 papers), Endometrial and Cervical Cancer Treatments (16 papers) and Uterine Myomas and Treatments (7 papers). Michel Préfontaine is often cited by papers focused on Ovarian cancer diagnosis and treatment (20 papers), Endometrial and Cervical Cancer Treatments (16 papers) and Uterine Myomas and Treatments (7 papers). Michel Préfontaine collaborates with scholars based in Canada, United States and United Kingdom. Michel Préfontaine's co-authors include Jacob McGee, Monique Bertrand, Yudith Ramos Valdés, Gabriel E. DiMattia, Trevor G. Shepherd, Kieran J. Murphy, G. OʼConnell, Akira Sugimoto, Akira Sugimoto and John L. Powell and has published in prestigious journals such as Cancer, International Journal of Radiation Oncology*Biology*Physics and Magnetic Resonance in Medicine.

In The Last Decade

Michel Préfontaine

39 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Préfontaine Canada 17 289 271 179 148 134 42 734
E Sun Paik South Korea 15 268 0.9× 224 0.8× 119 0.7× 102 0.7× 97 0.7× 42 556
S Mancuso Italy 16 311 1.1× 510 1.9× 110 0.6× 208 1.4× 174 1.3× 51 966
Yukihisa Minagawa Japan 16 213 0.7× 173 0.6× 188 1.1× 136 0.9× 198 1.5× 35 572
Paul N. Staats United States 20 286 1.0× 285 1.1× 183 1.0× 194 1.3× 199 1.5× 61 1.0k
Juhani Mäenpää Finland 17 305 1.1× 289 1.1× 175 1.0× 77 0.5× 201 1.5× 75 943
Bradley R. Corr United States 14 202 0.7× 210 0.8× 154 0.9× 95 0.6× 246 1.8× 64 699
Moon‐Hong Kim South Korea 17 274 0.9× 505 1.9× 117 0.7× 210 1.4× 167 1.2× 30 841
Marie‐Françoise Pelte Switzerland 16 255 0.9× 205 0.8× 109 0.6× 193 1.3× 155 1.2× 24 836
Iwona Podzielinski United States 10 492 1.7× 309 1.1× 164 0.9× 173 1.2× 148 1.1× 18 768
Eliane T. Taube Germany 15 316 1.1× 162 0.6× 175 1.0× 66 0.4× 165 1.2× 53 637

Countries citing papers authored by Michel Préfontaine

Since Specialization
Citations

This map shows the geographic impact of Michel Préfontaine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Préfontaine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Préfontaine more than expected).

Fields of papers citing papers by Michel Préfontaine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Préfontaine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Préfontaine. The network helps show where Michel Préfontaine may publish in the future.

Co-authorship network of co-authors of Michel Préfontaine

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Préfontaine. A scholar is included among the top collaborators of Michel Préfontaine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Préfontaine. Michel Préfontaine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thiryayi, S. A., Helen C. Ettler, Michel Préfontaine, et al.. (2021). BCOR Internal Tandem Duplication Associated Uterine Sarcoma: Expanding the Clinicopathologic Spectrum. International Journal of Gynecological Pathology. 41(5). 503–507. 5 indexed citations
2.
Velker, Vikram, David D’Souza, Michel Préfontaine, Jacob McGee, & Eric Leung. (2016). Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?. International Journal of Gynecological Cancer. 26(3). 491–496. 10 indexed citations
3.
Huang, Kitty, David D’Souza, Nikhilesh Patil, et al.. (2016). High-dose-rate interstitial brachytherapy for the treatment of high-volume locally recurrent endometrial carcinoma. Brachytherapy. 15(5). 543–548. 22 indexed citations
4.
Préfontaine, Michel, Vikram Velker, David D’Souza, & Eric Leung. (2015). The role of adjuvant therapy for stage IA serous and clear cell uterine cancer; is observation a valid strategy?. Gynecologic Oncology. 139(3). 589–589.
5.
Correa, Rohann, Yudith Ramos Valdés, Elena N. Fazio, et al.. (2014). Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis. 35(9). 1951–1961. 60 indexed citations
6.
Kupets, Rachel, Tien Le, Tien Le, et al.. (2013). Archivée: Rôle du traitement adjuvant en matière de cancer de l’endomètre. Journal of Obstetrics and Gynaecology Canada. 35(4). 377–379. 1 indexed citations
7.
Kupets, Rachel, Tien Le, Tien Le, et al.. (2013). RETIRED: The Role of Adjuvant Therapy in Endometrial Cancer. Journal of Obstetrics and Gynaecology Canada. 35(4). 375–376. 17 indexed citations
8.
Patil, Nikhilesh, Kathleen Surry, Akira Sugimoto, et al.. (2012). MRI Guided High-dose-rate Vaginal Interstitial Brachytherapy for Locally Recurrent Endometrial Cancers. International Journal of Radiation Oncology*Biology*Physics. 84(3). S459–S459. 1 indexed citations
9.
Vilos, George A., Jennifer Marks, Helen C. Ettler, et al.. (2012). Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Diagnostic Challenges and Therapeutic Dilemmas. Report of 2 Cases and Review of the Literature. Journal of Minimally Invasive Gynecology. 19(3). 288–295. 39 indexed citations
10.
Otis, Christopher N., et al.. (2008). Cystic Struma Ovarii (With Macrocystic Change). International Journal of Surgical Pathology. 16(4). 433–434.
11.
Préfontaine, Michel, et al.. (1999). Blindness as a Consequence of a Paraneoplastic Syndrome in a Woman with Clear Cell Carcinoma of the Ovary. Gynecologic Oncology. 73(3). 424–429. 16 indexed citations
12.
Préfontaine, Michel, et al.. (1997). Mesenteric small-bowel polyposis: a diagnostic radiographic sign of neurofibromatosis.. American Journal of Roentgenology. 168(2). 434–436. 1 indexed citations
13.
Préfontaine, Michel, et al.. (1996). Treatment of Refractory Ovarian Cancer with 5-Fluorouracil and Leucovorin. Gynecologic Oncology. 61(2). 249–252. 16 indexed citations
14.
Steinmetz, Oren K., Pierre Bédard, Michel Préfontaine, Michael Bourke, & G G Barber. (1996). Uterine tumor in the heart: Intravenous leiomyomatosis. Surgery. 119(2). 226–229. 28 indexed citations
15.
Préfontaine, Michel, et al.. (1994). Reproducibility of Tumor Measurements in Ovarian Cancer: A Study of Interobserver Variability. Gynecologic Oncology. 55(1). 87–90. 34 indexed citations
16.
Kuesel, Annette C., et al.. (1992). Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. International Journal of Cancer. 52(3). 341–346. 25 indexed citations
17.
Préfontaine, Michel, et al.. (1991). Evaluation of a simple line width test involving magnetic resonance spectroscopy of plasma in carcinoma of the ovary. Cancer. 67(2). 406–411. 4 indexed citations
18.
19.
Chmurny, Gwendolyn N., Bruce D. Hilton, Douglas Halverson, et al.. (1988). An NMR blood test for cancer: a critical assessment. NMR in Biomedicine. 1(3). 136–150. 37 indexed citations
20.
OʼConnell, G., et al.. (1987). Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.. PubMed. 70(6). 930–2. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Sun Paik Breakdown of academic impact, for papers by S Mancuso Breakdown of academic impact, for papers by Yukihisa Minagawa Breakdown of academic impact, for papers by Paul N. Staats Breakdown of academic impact, for papers by Juhani Mäenpää Breakdown of academic impact, for papers by Bradley R. Corr Breakdown of academic impact, for papers by Moon‐Hong Kim Breakdown of academic impact, for papers by Marie‐Françoise Pelte Breakdown of academic impact, for papers by Iwona Podzielinski Breakdown of academic impact, for papers by Eliane T. Taube
Rankless by CCL
2026